(Q33910781)

30 July 2017

8 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

3 October 2019

26 October 2020

An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review (English)

1 reference

30 July 2017

8 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

3 October 2019

26 October 2020

8 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

3 October 2019

26 October 2020

immunosuppressive drug

1 reference

26 October 2020

Robert J Barry

5

0 references

Alastair K. Denniston

object named as

Alastair K Denniston

4

0 references

Philip I. Murray

object named as

Philip I Murray

3

0 references

author name string

Thomas W McNally

1

1 reference

30 July 2017

Erika M Damato

2

1 reference

30 July 2017

language of work or name

1 reference

17 July 2017

9 references

Orphanet Journal of Rare Diseases

30 July 2017

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

3 October 2019

26 October 2020

9 references

30 July 2017

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

3 October 2019

26 October 2020

12

1 reference

30 July 2017

1

1 reference

30 July 2017

130

1 reference

Creative Commons Attribution 4.0 International

30 July 2017

8 references

12 March 2019

13 March 2019

21 March 2019

22 April 2019

25 April 2019

17 June 2019

3 October 2019

on focus list of Wikimedia project

26 October 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13023-017-0681-6

0 references

cites work

Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Behçet's syndrome: a critical digest of the 2014-2015 literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Behçet's syndrome patients exhibit specific microbiome signature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Pharmacotherapy for uveitis: current management and emerging therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Tocilizumab in severe and refractory non-infectious uveitis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Ethnicity and association with disease manifestations and mortality in Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Evidence-based practice in Behçet's disease: identifying areas of unmet need for 2014.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

High prevalence of Behçet's disease in southern Italy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Assessing the safety of biologic agents in patients with rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

High dose infliximab in the treatment of refractory uveitis: does dose matter?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Structural basis of immunosuppression by the therapeutic antibody daclizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Clinical experience with adalimumab in the treatment of ocular Behçet disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Interleukin-17 and its expanding biological functions.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Mycophenolate mofetil for ocular inflammation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Neuro-Behçet's disease: epidemiology, clinical characteristics, and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Treatment of retinal vasculitis in Behçet's disease with rituximab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

EULAR recommendations for the management of Behçet disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: a seventeen-year population-based study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Adalimumab for sight-threatening uveitis in Behçet's disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Current concepts in the etiology and treatment of Behçet disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Interleukin-17 family members and inflammation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

The use of interferon alpha in Behçet disease: review of the literature

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Description of Behçet's syndrome in the Hippocratic third book of endemic diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Behçet's disease: a new target for anti-tumour necrosis factor treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Systemic corticosteroid therapy--side effects and their management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Uveitis in Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Causes and frequency of blindness in patients with intraocular inflammatory disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Familial Behçet's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Uveitis in Behçet disease: an analysis of 880 patients.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Intravenous daclizumab for recalcitrant ocular inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Effects of interferon alpha treatment on the clinical course of refractory Behçet's disease: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Interferon alfa-associated depression in patients with Behçet's syndrome: a prospective controlled study.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Cytokines and Behcet's disease

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet's disease.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Behçet's disease in southern Chinese patients.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5513401

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

29 October 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Behçet Disease-associated Uveitis Successfully Treated with Golimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Anakinra treatment in drug-resistant Behcet’s disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2FS13023-017-0681-6

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study

21 January 2018

1 reference

12 December 2020

Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease

1 reference

12 December 2020

Role of gammadelta T lymphocytes in the development of Behçet's disease

1 reference

12 December 2020

Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials

1 reference

12 December 2020

Results of interferon alpha-2a therapy in patients with Behcet's disease

1 reference

12 December 2020

Enhancement of endothelial cell E-selectin expression by sera from patients with active Behçet's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels

1 reference

12 December 2020

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

12 December 2020

Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease

1 reference

12 December 2020

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

12 December 2020

Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis

1 reference

12 December 2020

1 reference

12 December 2020

Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity

1 reference

12 December 2020

Interferon Alpha-2a Therapy in Patients with Refractory Behçet Uveitis

1 reference

12 December 2020

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab

1 reference

12 December 2020

Oligoclonal B lymphocyte expansion in the synovium of a patient with Behçet's disease

1 reference

12 December 2020

Impaired prostacyclin synthesis by vessel walls in Behçet's disease

1 reference

12 December 2020

Impaired endothelium-dependent flow-mediated dilation in Behçet's disease: more prominent endothelial dysfunction in patients with vascular involvement

1 reference

12 December 2020

Efficacy of etanercept in the treatment of a patient with Behçet's disease

1 reference

12 December 2020

Recognition of B-cell epitopes of the 65 kDa HSP in Behçet's disease

1 reference

12 December 2020

Behçet's disease: an update on the pathogenesis

1 reference

12 December 2020

Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets

1 reference

12 December 2020

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

12 December 2020

Familial Behçet's disease of adult age: a report of 4 cases from a Behçet family

1 reference

12 December 2020

1 reference

12 December 2020

Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases.

1 reference

12 December 2020

Treatment of ocular inflammatory disorders with daclizumab

1 reference

12 December 2020

10.1186/S13023-017-0681-6

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference